Lan-Zhen Wang

1.3k total citations
16 papers, 899 citations indexed

About

Lan-Zhen Wang is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Lan-Zhen Wang has authored 16 papers receiving a total of 899 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 13 papers in Oncology and 3 papers in Organic Chemistry. Recurrent topics in Lan-Zhen Wang's work include Cancer-related Molecular Pathways (8 papers), DNA Repair Mechanisms (4 papers) and PARP inhibition in cancer therapy (4 papers). Lan-Zhen Wang is often cited by papers focused on Cancer-related Molecular Pathways (8 papers), DNA Repair Mechanisms (4 papers) and PARP inhibition in cancer therapy (4 papers). Lan-Zhen Wang collaborates with scholars based in United Kingdom, United States and Saudi Arabia. Lan-Zhen Wang's co-authors include David R. Newell, Nicola J. Curtin, Zdeněk Hostomský, Suzanne Kyle, Jane Endicott, M.E.M. Noble, Stephen E. Webber, Huw D. Thomas, Karen A. Maegley and Donald J. Skalitzky and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Molecular Biology and Clinical Cancer Research.

In The Last Decade

Lan-Zhen Wang

16 papers receiving 888 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lan-Zhen Wang United Kingdom	14	553	520	172	109	87	16	899
Frankie Lam Australia	18	479 0.9×	304 0.6×	278 1.6×	194 1.8×	42 0.5×	20	889
Elena Casale Italy	15	602 1.1×	253 0.5×	256 1.5×	70 0.6×	135 1.6×	28	965
Xiaoling Cockcroft United Kingdom	11	857 1.5×	717 1.4×	326 1.9×	58 0.5×	52 0.6×	15	1.3k
Carsten Schultz‐Fademrecht Germany	20	804 1.5×	452 0.9×	469 2.7×	87 0.8×	74 0.9×	38	1.2k
Yanke Liang United States	16	1.3k 2.4×	646 1.2×	181 1.1×	239 2.2×	86 1.0×	23	1.7k
Rachel E. Davis United States	11	606 1.1×	394 0.8×	273 1.6×	111 1.0×	87 1.0×	16	970
Mingfeng Yu Australia	21	674 1.2×	443 0.9×	347 2.0×	273 2.5×	83 1.0×	53	1.3k
Nicole Streiner United States	9	1.1k 2.1×	312 0.6×	159 0.9×	46 0.4×	49 0.6×	16	1.4k
Keith R. Hornberger United States	15	805 1.5×	371 0.7×	405 2.4×	51 0.5×	88 1.0×	18	1.2k
Sylvie Gomez United Kingdom	6	532 1.0×	461 0.9×	171 1.0×	54 0.5×	34 0.4×	6	825

Countries citing papers authored by Lan-Zhen Wang

Since Specialization

Citations

This map shows the geographic impact of Lan-Zhen Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lan-Zhen Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lan-Zhen Wang more than expected).

Fields of papers citing papers by Lan-Zhen Wang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lan-Zhen Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lan-Zhen Wang. The network helps show where Lan-Zhen Wang may publish in the future.

Co-authorship network of co-authors of Lan-Zhen Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Lan-Zhen Wang. A scholar is included among the top collaborators of Lan-Zhen Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lan-Zhen Wang. Lan-Zhen Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Wood, D.J., Richard A. Heath, James R. Ault, et al.. (2021). Discriminative SKP2 Interactions with CDK-Cyclin Complexes Support a Cyclin A-Specific Role in p27KIP1 Degradation. Journal of Molecular Biology. 433(5). 166795–166795. 16 indexed citations

Wood, D.J., S. Korolchuk, Natalie J. Tatum, et al.. (2018). Differences in the Conformational Energy Landscape of CDK1 and CDK2 Suggest a Mechanism for Achieving Selective CDK Inhibition. Cell chemical biology. 26(1). 121–130.e5. 106 indexed citations

Beale, Gary, Emma J. Haagensen, Huw D. Thomas, et al.. (2016). Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo antitumour activity in colorectal cancer. British Journal of Cancer. 115(6). 682–690. 45 indexed citations

Lochhead, Pamela A., Jonathan Clark, Lan-Zhen Wang, et al.. (2016). Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferation. Cell Cycle. 15(4). 506–518. 22 indexed citations

Boschi, Donatella, Paolo Tosco, Roberta Fruttero, et al.. (2013). 6-Cyclohexylmethoxy-5-(cyano-NNO-azoxy)pyrimidine-4-amine: A new scaffold endowed with potent CDK2 inhibitory activity. European Journal of Medicinal Chemistry. 68. 333–338. 13 indexed citations

Baumli, Sonja, Alison J. Hole, Lan-Zhen Wang, M.E.M. Noble, & Jane Endicott. (2012). The CDK9 Tail Determines the Reaction Pathway of Positive Transcription Elongation Factor b. Structure. 20(10). 1788–1795. 27 indexed citations

Thomas, Huw D., Lan-Zhen Wang, Johanne Bentley, et al.. (2011). Preclinical in vitro and in vivo evaluation of the potent and specific cyclin-dependent kinase 2 inhibitor NU6102 and a water soluble prodrug NU6301. European Journal of Cancer. 47(13). 2052–2059. 13 indexed citations

Wong, Christopher, Roger J. Griffin, Ian R. Hardcastle, et al.. (2010). Synthesis of sulfonamide-based kinase inhibitors from sulfonates by exploiting the abrogated SN2 reactivity of 2,2,2-trifluoroethoxysulfonates. Organic & Biomolecular Chemistry. 8(10). 2457–2457. 14 indexed citations

Thomas, Huw D., Lan-Zhen Wang, Julian S. Northen, et al.. (2009). Preclinical evaluation of a novel pyrimidopyrimidine for the prevention of nucleoside and nucleobase reversal of antifolate cytotoxicity. Molecular Cancer Therapeutics. 8(7). 1828–1837. 8 indexed citations

10.

Scrace, Simon, Jenifer Borgognoni, Lan-Zhen Wang, et al.. (2008). Transient treatment with CDK inhibitors eliminates proliferative potential even when their abilities to evoke apoptosis and DNA damage are blocked. Cell Cycle. 7(24). 3898–3907. 15 indexed citations

11.

Thomas, Huw D., Christopher Calabrese, Michael A. Batey, et al.. (2007). Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. Molecular Cancer Therapeutics. 6(3). 945–956. 233 indexed citations

12.

Griffin, Roger J., Andrew Henderson, Nicola J. Curtin, et al.. (2006). Searching for Cyclin-Dependent Kinase Inhibitors Using a New Variant of the Cope Elimination. Journal of the American Chemical Society. 128(18). 6012–6013. 65 indexed citations

13.

Tikhe, Jayashree, Stephen E. Webber, Zdeněk Hostomský, et al.. (2004). Design, Synthesis, and Evaluation of 3,4-Dihydro-2H-[1,4]diazepino[6,7,1-hi]indol-1-ones as Inhibitors of Poly(ADP-Ribose) Polymerase. Journal of Medicinal Chemistry. 47(22). 5467–5481. 33 indexed citations

14.

Hardcastle, Ian R., Christine E. Arris, Johanne Bentley, et al.. (2004). N²-Substituted O⁶-Cyclohexylmethylguanine Derivatives: Potent Inhibitors of Cyclin-Dependent Kinases 1 and 2. Journal of Medicinal Chemistry. 47(15). 3710–3722. 105 indexed citations

15.

Curtin, Nicola J., Lan-Zhen Wang, Anthie Yiakouvaki, et al.. (2004). Novel Poly(ADP-ribose) Polymerase-1 Inhibitor, AG14361, Restores Sensitivity to Temozolomide in Mismatch Repair-Deficient Cells. Clinical Cancer Research. 10(3). 881–889. 120 indexed citations

16.

Calabrese, Christopher, Michael A. Batey, Huw D. Thomas, et al.. (2003). Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies.. PubMed. 9(7). 2711–8. 64 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact